Oman

Roche’s filing for Elevidys in the EU followed applications in Middle Eastern countries because those markets accept applications based on approval by the US Food and Drugs Administration.

UK R&D firm Futura Medical strikes third commercial agreement for its drug-free erectile dysfunction treatment MED3000, this time with Switzerland’s Labatec Pharma, which will take the drug-free gel to the Middle East. 

Vivimed Labs, an Indian specialty chemicals and pharmaceuticals manufacturer and exporter, has raised Rs1.27 billion ($27.6 million) via a preferential offer to the private equity investors Jacob Ballas and Kitara Capital.